Preclinical study to assess CAR-Treg cells for neuroinflammation
PolTREG has launched a preclinical study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease.
The study will measure the safety and efficacy of the therapy and data is anticipated by March 2025.
PolTREG’s CAR-Treg cells are manufactured using the same technology platform as PTG-007, a polyclonal Treg cell therapy.
“This first preclinical study of our CAR-Treg cell therapy programme to treat neurodegenerative disease is a significant milestone for PolTREG. This may be our first CAR-Treg cell therapy candidate, but we expect it to benefit tremendously from the experience our team built up during more than a decade in manufacturing, developing and treating patients with PTG-007,” said Professor Piotr Trzonkowski, Chief Executive Officer of PolTREG.
PTG-007 is an autologous polyclonal product candidate for which the company has gathered 12 years of patient safety and efficacy data in type 1 diabetes.
In an exploratory Phase I/II2a safety study in relapsing-remitting multiple sclerosis (MS), patients who had received intrathecal administration of PTG-007 showed no increase in existing lesions in the brain, and almost no new lesions, a far superior result compared to those who had received the therapy intravenously.
On successful completion of preclinical testing of the CAR-Treg, PolTREG expects to initiate, as early as next year, the first-in-human trial of the engineered candidate to treat MS and amyotrophic lateral sclerosis (ALS).
The company is also developing two additional modalities of engineered Treg cell therapies, Antigen-specific Tregs and T-cell receptor (TCR) Tregs for autoimmune diseases, which are in early, proof-of-concept preclinical stages.
Diana Spencer, Senior Digital Content Editor, DDW
